Table 1.
Subject characteristics
| Variable | |
|---|---|
| Age (years) | 67 ± 14 |
| Male | 90 (62) |
| Race | |
| Caucasian | 82 (57) |
| African-American | 28 (19) |
| Hispanic | 20 (14) |
| Asian | 15 (10) |
| Body mass index (kg m−2) | 29 ± 7 |
| Smoker | 6 (4) |
| Primary indication for anticoagulation | |
| Atrial fibrillation | 106 (73) |
| DVT or PE | 21 (15) |
| Other | 18 (12) |
| Number of concurrent medications | 5.7 ± 2.9 |
| Number of concurrent medications that interact with warfarin | |
| 0 | 46 (32) |
| 1 | 56 (39) |
| ≥ 2 | 43 (30) |
| Mean therapeutic warfarin dose (mg per week) | 40 ± 26 |
| Median therapeutic warfarin dose (mg per week) | 35 (23, 53) |
| Non-compliance score | |
| 0 | 132 (91) |
| 1 | 13 (9) |
DVT, deep vein thrombosis; PE, pulmonary embolism.
Total number of subjects = 145. Data presented as mean ± SD, median (interquartile range), or n (%).